HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Langen, K.-J. Articles by Feinendegen, L. E. Search for Related Content PubMed PubMed Citation Articles by Langen, K.-J. Articles by Feinendegen, L. E.

Brain and Brain Tumor Uptake of L-3-[¹²³I]Iodo--Methyl Tyrosine: Competition with Natural L-Amino Acids

Institute of Medicine and Institute of Chemistry 1, Research Center Jülich, Jülich, Germany; Department of Neurosurgery, Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany

Correspondence: For reprints contact: Karl-Josef Langen, MD, Institute of Medicine, Research Center Jülich, POB 1913, 5170 Jülich, Germany.

ABSTRACT

SPECT studies with L-3-[¹²³I]iodo--methyl tyrosine (IMT) were carried out in 10 patients with different types of brain tumors—first under fasting conditions (basal) and a week later during intravenous infusion of a mixture of naturally-occurring L-amino acids (AA load). An uptake index (UI) was calculated by dividing tissue count rates by the integral of plasma count rates. The UI decreased by 45.6% ± 15.4% (n = 10, p < 0.001) for normal brain and by 53.2% ± 14.1% for gliomas (n = 5, p < 0.01) during AA load compared to basal conditions, while two meningliomas and a metastasis showed only a minor decrease (23.9 ± 5.7%, n.s). Two pituitary adenomas could not be delineated on the SPECT-scans. These data indicate that IMT competes with naturally-occurring L-amino acids for transport into normal brain and gliomas. Transport characteristics of IMT into tumors of non-gliomas origin appear to be different from those of gliomas. For both types of tumors, it is advisable to perform IMT-SPECT under fasting conditions.

This article has been cited by other articles:

				M. Henze, A. Mohammed, H. P. Schlemmer, K. K. Herfarth, S. Hoffner, S. Haufe, W. Mier, M. Eisenhut, J. Debus, and U. Haberkorn PET and SPECT for Detection of Tumor Progression in Irradiated Low-Grade Astrocytoma: A Receiver-Operating-Characteristic Analysis J. Nucl. Med., April 1, 2004; 45(4): 579 - 586. [Abstract] [Full Text] [PDF]

				N. Shikano, K. Kawai, L. G. Flores II, R. Nishii, N. Kubota, N. Ishikawa, and A. Kubodera An Artificial Amino Acid, 4-Iodo-L-meta-Tyrosine: Biodistribution and Excretion via Kidney J. Nucl. Med., April 1, 2003; 44(4): 625 - 631. [Abstract] [Full Text] [PDF]

				B. Riemann, K. Papke, N. Hoess, T. Kuwert, M. Weckesser, P. Matheja, H. Wassmann, W. Heindel, and O. Schober Noninvasive Grading of Untreated Gliomas: A Comparative Study of MR Imaging and 3-(Iodine 123)-L-{alpha}-methyltyrosine SPECT Radiology, November 1, 2002; 225(2): 567 - 574. [Abstract] [Full Text] [PDF]

				T. Lahoutte, V. Caveliers, P. R. Franken, A. Bossuyt, J. Mertens, and H. Everaert Increased Tumor Uptake of 3-123I-Iodo-L-{alpha}-Methyltyrosine After Preloading with Amino Acids: An In Vivo Animal Imaging Study J. Nucl. Med., September 1, 2002; 43(9): 1201 - 1206. [Abstract] [Full Text] [PDF]

				P. L. Jager Improving Amino Acid Imaging: Hungry or Stuffed? J. Nucl. Med., September 1, 2002; 43(9): 1207 - 1209. [Full Text] [PDF]

				S. Samnick, J. B. Bader, D. Hellwig, J. R. Moringlane, C. Alexander, B. F.M. Romeike, W. Feiden, and C.-M. Kirsch Clinical Value of Iodine-123-Alpha-Methyl-L-Tyrosine Single-Photon Emission Tomography in the Differential Diagnosis of Recurrent Brain Tumor in Patients Pretreated for Glioma at Follow-Up J. Clin. Oncol., January 15, 2002; 20(2): 396 - 404. [Abstract] [Full Text] [PDF]

				E. C. H. Friesema, R. Docter, E. P. C. M. Moerings, F. Verrey, E. P. Krenning, G. Hennemann, and T. J. Visser Thyroid Hormone Transport by the Heterodimeric Human System L Amino Acid Transporter Endocrinology, October 1, 2001; 142(10): 4339 - 4348. [Abstract] [Full Text] [PDF]

				T. Inoue, K. Koyama, N. Oriuchi, S. Alyafei, Z. Yuan, H. Suzuki, K. Takeuchi, Y. Tomaru, K. Tomiyoshi, J. Aoki, et al. Detection of Malignant Tumors: Whole-Body PET with Fluorine 18 {{alpha}}-Methyl Tyrosine versus FDG—Preliminary Study Radiology, July 1, 2001; 220(1): 54 - 62. [Abstract] [Full Text] [PDF]

				P. L. Jager, W. Vaalburg, J. Pruim, E. G.E. de Vries, K.-J. Langen, and D. A. Piers Radiolabeled Amino Acids: Basic Aspects and Clinical Applications in Oncology J. Nucl. Med., March 1, 2001; 42(3): 432 - 445. [Abstract] [Full Text]

				M. M. Graham Combined 18F-FDG-FDOPA Tumor Imaging for Assessing Response to Therapy J. Nucl. Med., February 1, 2001; 42(2): 257 - 258. [Full Text]

				P. L. Jager, W. G. Meijer, I. P. Kema, P. H.B. Willemse, D. A. Piers, and E. G.E. de Vries L-3-[123I]Iodo-{alpha}-Methyltyrosine Scintigraphy in Carcinoid Tumors: Correlation with Biochemical Activity and Comparison with [111In-DTPA-D-Phe1]-Octreotide Imaging J. Nucl. Med., November 1, 2000; 41(11): 1793 - 1800. [Abstract] [Full Text] [PDF]

				P. L. Jager, B. E. C. Plaat, E. G. E. de Vries, W. M. Molenaar, W. Vaalburg, D. A. Piers, and H. J. Hoekstra Imaging of Soft-Tissue Tumors Using L-3-[Iodine-123]Iodo-{{alpha}}-methyl-tyrosine Single Photon Emission Computed Tomography: Comparison with Proliferative and Mitotic Activity, Cellularity, and Vascularity Clin. Cancer Res., June 1, 2000; 6(6): 2252 - 2259. [Abstract] [Full Text]